Mankind Pharma Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Mankind Pharma Ltd. from all sources in a single place.

Load latest

03 Aug 2023

2572.70

0.50%

Mankind Pharma Results Earnings Call for Q1FY24

Conference Call with Mankind Pharma Management and Analysts on Q1FY24 Performance and Outlook. Listen to the full earnings transcript.

audio

Mankind Pharma Ltd.

03 Aug 2023

2572.70

0.50%

Company Update

Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith extracts of the Consolidated Unaudited Financial Results for the quarter ended June 30, 2023 as published in "Financial Express" and "Jansatta" on August 03, 2023.

pdf

Mankind Pharma Ltd.

03 Aug 2023

2572.70

0.50%

to see Rapid results content

Mankind Pharma Ltd.

03 Aug 2023

2572.70

0.50%

Mankind Pharma share price jumps over 8% on robust Q1 results

livemint

Mankind Pharma stock price jumps 8% after strong Q1FY24 results, reaching near 52-week high level.

Mankind Pharma Ltd. is trading above all available SMAs

Mankind Pharma soars 9% as investors cheer stellar Q1 earnings

Moneycontrol | 03 Aug 2023 2 more

Mankind Pharma Ltd.

02 Aug 2023

2572.70

0.50%

Company Update

Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Press Release on Financial Results for the quarter ended June 30, 2023.

pdf

Mankind Pharma Ltd.

02 Aug 2023

2572.70

0.50%

Investor Presentation

Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Investor Presentation

BSE India

Investor Presentation of Q1FY2023-24

pdf

Mankind Pharma Ltd.

02 Aug 2023

2572.70

0.50%

Company Update

Mankind Pharma Ltd - 543904 - Outcome Of Board Meeting

BSE India

The Board at its meeting held on 02nd August, 2023 has inter alia approved the following: 1. Re-appointment of Mr. Ramesh Juneja as Chairman and Whole Time Director. 2. Re-appointment of Mr. Rajeev Juneja as Vice Chairman and Managing Director. 3. Re-appointment of Mr. Sheetal Arora as Whole-time Director and Chief Executive Officer. 4. Re-designation of Mr. Suresh Raju Penmetsa as Chief Risk Officer and Vice President EHS. 5. Re-appointment of M/s Dayal & Maur, Company Secretaries as the Secretarial Auditor of the Company for the FY 2023-24. 6. Ratification of Mankind Employee Stock Option Plan 2022. 7. Ratification of grant of employee stock option to the employees of subsidiary company(ies)/Group Company/ Associate Companies. Item no. 1, 2, 3, 6 and 7 are subject to approval of the members of the Company.

pdf

Mankind Pharma Ltd.

02 Aug 2023

2572.70

0.50%

Board Meeting

Mankind Pharma Ltd - 543904 - Board Meeting Outcome for Outcome Of Board Meeting Held Today …

BSE India

Outcome of Board Meeting as per letter attached

pdf

Mankind Pharma Ltd.

02 Aug 2023

2572.70

0.50%

Result

Mankind Pharma Ltd - 543904 - Regulation 30 And 33 Of The SEBI (Listing Obligations And …

BSE India

Outcome of Board Meeting as per letter attached.

pdf

Mankind Pharma Ltd.

21 Jul 2023

2572.70

0.50%

Company Update

Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Company will host Investor Conference Call on Thursday, 03rdAugust 2023 at 12 noon (IST) for Q1FY24.